Skin & hair · Cream

AHK-Cu

Gray market

Checked 18 Oct 2026 · 19 sources · 15 corrections on this page · No vendors · No affiliates · No one buys a word of it

0 human trials published

Limited Evidence · one lab paper · Pyo 2007

Gray market · No FDA ruling — not on any list

Sold as a cosmetic ingredient in creams and serums.

Bottom line

GHK-Cu with one amino acid swapped, sold for hair instead of skin. One 2007 lab paper (Pyo et al., 2007) plus GHK-Cu's halo effect.

Also called: Alanine-Histidine-Lysine Copper
Ala-His-Lys:Cu²⁺
Copper Tripeptide-3
L-alanyl-L-histidyl-L-lysine-Cu²⁺
Ala-His-Lys-Cu
Category: Cosmetic Peptide — Copper Tripeptide (Hair)
Sequence: Ala-His-Lys · Cu²⁺
Class: Synthetic copper tripeptide
Molecular Weight: 354.4 Da (the AHK peptide; the copper complex is heavier)
Route (studied): Cells only · no animal or human study
Route (sold): Topical scalp serums (cosmetic); powder (formulators)
FDA Status: Cosmetic ingredient
Primary Target: Dermal papilla cells (VEGF not measured)
Published Studies: One, in cells and organ-cultured hair follicles
WADA Status: Not listed (N/A topical)
Cost & Access: Cosmetic ingredient

Also for skin & hair

The other four questions

What does it do? In one lab study, it made cultured cells from the base of hair follicles multiply and lengthened human hair follicles kept in a dish; fewer of the cells died, though not significantly (Pyo et al., 2007).
Who uses it? Cosmetic formulators, in hair-growth serums; some serums add GHK-Cu, and some are sold as add-ons to minoxidil.
Does the evidence hold up? The entire story rests on one 2007 lab paper in a Korean pharmacology journal (Pyo et al., 2007). Zero studies of AHK-Cu in people, randomized or not. The rest is extrapolated from GHK-Cu.
Bottom line? GHK-Cu with one amino acid swapped, sold for hair instead of skin. One 2007 lab paper (Pyo et al., 2007) plus GHK-Cu's halo effect.

Dosing from the Literature

Published for hair: lab-dish concentrations only (Pyo et al., 2007). Not published: any human dose-response study; the serum percentages below are cosmetic formulation practice.

AHK-Cu is a cosmetic ingredient, so its "dose" is its percentage in a leave-on scalp product. No study has tested it in people at any dose; PubMed and ClinicalTrials.gov list none. The only published concentrations are the lab-dish ones (10⁻¹² – 10⁻⁹ M) of Pyo et al. (2007).

Formulation	Concentration	Application	Source
Leave-on hair-growth serum	0.05–0.2% AHK-Cu	Scalp / hairline / vertex / crown	Cosmetic formulation practice
Standalone "high-strength" copper-peptide serum	0.2–0.5% AHK-Cu	Scalp affected areas	Cosmetic formulation practice
AHK-Cu + GHK-Cu combination serum	0.1% each (0.2% total)	Scalp, beard, or hairline	What commercial serums list
In-vitro active range (Pyo 2007)	10⁻¹² – 10⁻⁹ M (≈ 0.35 pg/mL to 0.35 ng/mL)	Cell-culture medium	Lab study: cultured dermal papilla cells and human hair follicles in organ culture (Pyo et al., 2007)

No study has measured how much AHK-Cu passes through the skin from any product.

Dosing Disclaimer

The percentages above are cosmetic formulation practice, not tested doses. AHK-Cu has no FDA-approved indication, no human pharmacokinetic profile, and no standard-of-care concentration recommendation, and no study has recorded its side effects in people. Starting a topical hair-loss regimen, especially in pregnancy, breastfeeding or autoimmune alopecia (alopecia areata, lichen planopilaris, frontal fibrosing alopecia), is a question for a licensed dermatologist or healthcare provider.

What It Is

AHK-Cu is a synthetic copper-binding tripeptide (a chain of 3 amino acids) composed of L-alanine, L-histidine, and L-lysine chelated to a divalent copper ion (Cu²⁺). The name Copper Tripeptide-3 is not in the EU's register of cosmetic ingredients, CosIng, whose Tripeptide-3 is a peptide of glycine, serine and valine; CosIng lists GHK-Cu, the plasma tripeptide Loren Pickart isolated in 1973 (Pickart et al., 2015, Biomed Res Int), as Copper Tripeptide-1. The peptide backbone — alanyl-histidyl-lysine — acts as a copper carrier, with histidine providing the primary nitrogen-donor coordination sphere around the Cu²⁺ ion and the alpha-amino and carboxyl termini contributing auxiliary copper-binding. Molecular weight of the peptide component is approximately 354 Da; the assembled AHK-Cu complex has an approximate molecular formula of C₁₅H₂₄CuN₆O₄.

Structurally, AHK-Cu differs from GHK-Cu by a single amino-acid substitution at position 1: alanine's methyl side-chain replaces glycine's single hydrogen. That one methyl group — an addition of CH₂ to the sidechain — changes the steric profile of the tripeptide without altering the copper-binding histidine or the lysine basic-charge anchor. The change is small in atomic terms; no published study has compared the two peptides, so whether it changes what the peptide does in cells is unknown.

AHK-Cu is not a naturally occurring human peptide. Unlike GHK-Cu — which is endogenous to human plasma, saliva, and urine at nanogram-per-milliliter concentrations that decline with age — AHK-Cu is a purely synthetic cosmetic active. It was engineered specifically as a scalp/hair-follicle-targeting analog to capture the copper-peptide mechanism while positioning clearly outside the anti-aging / wound-healing market that GHK-Cu dominates. Commercial availability is essentially entirely in the cosmetic channel: cosmetic-grade powders, which specialty peptide suppliers list at >95% HPLC purity, and ready-made hair serums. It is not an approved pharmaceutical in any jurisdiction; it is a cosmetic ingredient used in leave-on hair-growth topical products.

The published research base on AHK-Cu specifically is unusually thin for a compound that has been commercially available for nearly two decades. A single peer-reviewed study — Pyo et al., Archives of Pharmacal Research, 2007 (PMID 17703734) — provides the foundational mechanistic data on AHK-Cu in dermal papilla cells and ex vivo human hair follicles. Most subsequent AHK-Cu mentions in the literature are citations to that paper, derivative manufacturer-sponsored in-vitro assays on dermal fibroblast cultures, cosmetic-industry white papers, or comparator notes in GHK-Cu review articles. The vast majority of the supporting biology is drawn from the much larger GHK-Cu, VEGF-in-hair-follicle, and dermal-papilla-cell literature — extrapolated to AHK-Cu by structural analogy and shared copper-peptide mechanism.

Mechanism of Action

The only mechanism work on AHK-Cu itself is one 2007 study in cultured dermal papilla cells and in human hair follicles kept in organ culture (Pyo et al., 2007, PMID 17703734). The rest of this section comes from research on GHK-Cu and on VEGF in hair follicles, not on AHK-Cu.

Copper delivery via tripeptide chelate — Copper is a required cofactor for lysyl oxidase (collagen/elastin cross-linking), tyrosinase, dopamine-β-hydroxylase, superoxide dismutase, and cytochrome c oxidase — all of which contribute to scalp tissue homeostasis.
VEGF upregulation in dermal fibroblasts — The paper's abstract describes the copper tripeptide as raising VEGF production by cultured dermal fibroblasts (while lowering their TGF-β1 secretion); its own results, at 10⁻¹² to 10⁻⁹ M, are longer hair follicles ex vivo and more dermal papilla cell growth, and it reports no VEGF measurement in dermal papilla cells (Pyo et al., 2007, PMID 17703734). In transgenic VEGF-overexpression hair-follicle models, follicle size and hair shaft diameter increase measurably (Yano, Brown & Detmar, J Clin Invest, 2001, PMID 11181640); systemic anti-VEGF antibodies suppress follicle vascularization and shaft growth. In cultured dermal papilla cells, minoxidil raised VEGF, which the authors propose helps keep follicles supplied with blood vessels (Lachgar et al., Br J Dermatol, 1998, PMID 9580790).
Dermal papilla cell proliferation — AHK-Cu (10⁻¹² – 10⁻⁹ M) increased the proliferation of cultured dermal papilla cells (Pyo et al., 2007). DPCs are specialized mesenchymal cells at the base of each follicle that play pivotal roles in hair formation, growth and cycling (Matsuzaki & Yoshizato, 1998, PMID 9893172).
Ex vivo hair follicle elongation — In whole human scalp hair follicles cultured ex vivo, AHK-Cu stimulated elongation of the hair shaft at the same low picomolar-to-nanomolar concentration range (Pyo et al., 2007). Follicles in organ culture have no working blood supply: in cultured mouse whisker follicles, neither added VEGF nor VEGF blockade had any effect (Yano et al., 2001).
Anti-apoptotic signaling in DPCs — Bcl-2/Bax and caspase-3 — Annexin-V / PI flow cytometry in the Pyo 2007 work suggested a trend toward reduced apoptosis (programmed cell death) in 10⁻⁹ M AHK-Cu-treated DPCs (though the effect did not reach statistical significance). The Bcl-2-to-Bax ratio was elevated, and cleaved caspase-3 and cleaved PARP — downstream executioner-apoptosis markers — were reduced; the authors proposed that AHK-Cu promotes follicle growth, perhaps by stimulating these cells' proliferation and preventing their apoptosis (Pyo et al., 2007).
VEGFR2 / ERK downstream — VEGF-driven proliferation of human dermal papilla cells ran through VEGFR2 and ERK; in the same cells VEGF did not change Akt, p38 or JNK phosphorylation (Li et al., 2012, PMID 22659165).
Copper-peptide cross-talk with GHK-Cu biology — AHK-Cu and GHK-Cu differ only in the first amino acid: alanine in AHK-Cu (Pyo et al., 2007), glycine in GHK-Cu (Maquart et al., 1988). GHK-Cu is the canonical copper-peptide active — extensively characterized across wound healing, collagen synthesis, elastin synthesis, decorin, glycosaminoglycan deposition, anti-inflammatory signaling, anti-oxidant gene upregulation, and hair-follicle stimulation (Maquart et al., 1988, PMID 3169264; Pickart et al., Biomed Res Int 2015, PMID 26236730; Pickart & Margolina, Int J Mol Sci 2018, PMID 29986520). The AHK substitution is positioned as trading some of GHK-Cu's broader skin-regenerative profile for greater selectivity toward dermal papilla / follicle biology — a commercially-driven positioning rather than a rigorously mapped mechanistic bifurcation.
Keratinocyte involvement — In mice, VEGF mRNA rose in the follicular keratinocytes of the outer root sheath, not in the dermal papilla, as follicles grew (Yano et al., 2001); in cultured human follicle cells, dermal papilla cells expressed the most VEGF and keratinocytes less (Kozlowska et al., 1998, PMID 9879835).
Anti-oxidant role (shown for GHK) — In lab and animal studies, GHK blocked the formation of reactive oxygen and carbonyl species and detoxified lipid-peroxidation products such as acrolein, and the review proposes its effects on antioxidant-related genes as an explanation (Pickart et al., 2015, Cosmetics). In test-tube experiments, GHK-Cu inhibited lipid peroxidation driven by iron from ferritin and inhibited that iron's release, without significant superoxide-dismutase-like activity (Miller et al., 1990, PMID 2244543). None of this has been tested for AHK-Cu.

What the Research Shows

AHK-Cu's peer-reviewed research is a single lab study, in cultured dermal papilla cells and human hair follicles in organ culture (Pyo et al., 2007); no study has tested it in animals or people. The rest of the evidence below is borrowed from research on GHK-Cu, VEGF and dermal papilla cells. This is the compound's single most important scientific limitation.

Pyo et al. 2007 (PMID 17703734) — foundational in-vitro / ex-vivo study — Published in Archives of Pharmacal Research by Pyo, Yoo, Won, Lee, Kang, Eun, Cho, and Kim of Seoul National University College of Medicine. Tested L-alanyl-L-histidyl-L-lysine-Cu²⁺ (AHK-Cu) at concentrations 10⁻¹² to 10⁻⁹ M in cultured human dermal papilla cells (DPCs) and human scalp hair follicles in organ culture. Key findings: AHK-Cu stimulated follicle elongation ex vivo across the full concentration range; AHK-Cu stimulated DPC proliferation at the same concentrations; AHK-Cu reduced Annexin-V–positive apoptotic DPC fraction (trend, not statistically significant); Bcl-2/Bax ratio increased; cleaved caspase-3 and cleaved PARP decreased under 10⁻⁹ M AHK-Cu treatment. The abstract opens by describing the copper tripeptide as raising VEGF and lowering TGF-β1 secretion by dermal fibroblasts; those are not results of this study. This is the canonical AHK-Cu reference.
Copper-peptide + VEGF in follicle angiogenesis — Yano, Brown & Detmar 2001 (PMID 11181640) — Journal of Clinical Investigation. Landmark study demonstrating that VEGF is a major mediator of hair follicle growth and cycling. Transgenic VEGF overexpression in outer-root-sheath keratinocytes increased perifollicular vascularization, accelerated hair regrowth after depilation, and increased hair follicle and shaft size. Systemic anti-VEGF antibody treatment reduced follicle vascularization and shaft size. Establishes the mechanistic target AHK-Cu's VEGF-upregulation claim addresses.
Minoxidil VEGF upregulation in DPCs — Lachgar et al. 1998 (PMID 9580790) — British Journal of Dermatology. Minoxidil — the FDA-approved topical hair-growth drug — upregulates VEGF mRNA expression in cultured human hair dermal papilla cells. The authors propose that minoxidil helps keep follicles vascularized through VEGF; the finding is in cultured cells, so it is a proposed part of minoxidil's mechanism, not a clinically validated one. It places AHK-Cu in the same family only conceptually (even though AHK-Cu is a copper peptide and minoxidil is a potassium-channel opener with different upstream biology).
VEGF autocrine loop in DPCs — Lachgar et al. 1996 (PMID 8592070) — Identified VEGF as an autocrine growth factor for hair dermal papilla cells and demonstrated that DPC proliferation responds to VEGF in a dose-dependent manner. The autocrine loop provides a mechanistic substrate for AHK-Cu's stimulatory effect on DPC proliferation.
VEGF / VEGFR2 in DPCs — Li et al. 2012 (PMID 22659165) — Demonstrated VEGFR2 expression on human hair follicle dermal papilla cells and showed that VEGF induces DPC proliferation through VEGFR2-mediated ERK activation.
Foundational GHK-Cu collagen synthesis — Maquart et al. 1988 (PMID 3169264) — FEBS Letters. First demonstration that the tripeptide-copper complex GHK-Cu stimulates collagen synthesis in fibroblast cultures at concentrations 10⁻¹² to 10⁻⁹ M — the same active-concentration range later documented for AHK-Cu on dermal papilla cells. Establishes the copper-peptide class pharmacology at pico-to-nanomolar active concentrations.
GHK-Cu gene-expression review — Pickart & Margolina 2018 (PMID 29986520) — International Journal of Molecular Sciences. Comprehensive review of GHK-Cu biology using Connectivity-Map gene-expression data. Documents GHK-Cu's effects on anti-inflammatory, anti-oxidant, collagen-synthesis, and DNA-repair gene sets. The indirect scaffold for many AHK-Cu mechanistic claims.
GHK-Cu multi-pathway review — Pickart, Vasquez-Soltero & Margolina 2015 (PMID 26236730) — BioMed Research International. Broader Pickart review of copper-peptide pathways in skin regeneration. Backgrounds the copper-peptide mechanism framework used throughout the AHK-Cu literature.
VEGF expression across hair-follicle compartments — Kozlowska et al. 1998 (PMID 9879835) — Compared VEGF mRNA expression across dermal papilla cells, fibrous-sheath fibroblasts, dermal fibroblasts, and follicular and interfollicular keratinocytes. Dermal papilla cells expressed the most VEGF; follicular and interfollicular keratinocytes expressed less than the mesenchymal cells. Anchors AHK-Cu's dermal-papilla-centered positioning.
Skin-regenerative and anti-cancer actions of copper peptides — Pickart & Margolina 2018 — Cosmetics 5(2):29. Broad-spectrum review of copper-peptide therapeutics. Places AHK-Cu within the wider copper-peptide cosmetic and dermatological-science context.
No published human study — PubMed and ClinicalTrials.gov list no study of AHK-Cu in people, randomized or not.

Research Limitations

AHK-Cu is one of the clearest examples of a cosmetic peptide where commercial marketing substantially outpaces peer-reviewed evidence. The direct published database is essentially one in-vitro / ex-vivo paper (Pyo 2007). The supporting biology is drawn from GHK-Cu and general VEGF-in-follicle literature. No study of AHK-Cu in people has been published or registered (PubMed, ClinicalTrials.gov). AHK-Cu is not a validated hair-loss therapy.

Human Data

Unlike GHK-Cu — which has open-label cosmetic-panel data, a couple of small controlled hair studies, and a long wound-healing clinical footprint — AHK-Cu's human evidence base is minimal. The following is a candid inventory of what exists:

No published placebo-controlled double-blind RCT of AHK-Cu monotherapy. Searches of PubMed, Google Scholar, ClinicalTrials.gov, and the Cochrane Central Register do not identify a placebo-controlled double-blind randomized trial of AHK-Cu as a single active in human androgenetic alopecia or general hair-loss populations.
Combination-product context — minoxidil adjunct — AHK-Cu appears in multiple cosmetic serums positioned as a topical adjunct to minoxidil or finasteride therapy. No peer-reviewed head-to-head or adjunctive-therapy trial of AHK-Cu + minoxidil has been published to our knowledge.

The honest summary: no peer-reviewed study has tested AHK-Cu in people. Its case rests on one 2007 lab study (Pyo et al., 2007) and on research into GHK-Cu and VEGF in hair follicles.

Reconstitution & Storage

AHK-Cu is sold as a powder, to formulators, and ready-mixed in scalp serums. No published study gives conditions for mixing or storing it.

→ Calculator — vial-to-syringe math

Side Effects & Risks

No study has tested AHK-Cu in people, so none of its side effects has been measured: PubMed and ClinicalTrials.gov list no human study of it.

Systemic copper exposure — No study has measured how much of AHK-Cu's copper passes through intact or broken skin.
Wilson disease / copper overload — A theoretical concern only: AHK-Cu carries copper (Pyo et al., 2007), and no study has measured how much passes through the skin or tested it in people with Wilson disease, an inherited disorder of copper build-up.
Pregnancy and breastfeeding — No human reproductive-safety data: no study has tested AHK-Cu in people.
Pediatric use — No pediatric data.
Drug interactions — None has been studied.
No WADA relevance — AHK-Cu is a topical cosmetic copper peptide; it is not named on the WADA Prohibited List and is not a plausible candidate for anti-doping concern at cosmetic-use concentrations. Systemic peptide-analog concerns apply to injectable peptides, not topical copper-tripeptide actives.

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for AHK-Cu, and no study has tested it in people.

No WADA-relevant testing — AHK-Cu is topical and cosmetic, and the WADA Prohibited List does not name it.

Commonly Stacked With

No published study has tested AHK-Cu together with any other treatment. These are the pairings sellers describe:

GHK-Cu

Sellers list scalp serums that combine it with AHK-Cu, at about 0.1% of each. No study has tested the combination.

Tested together in people: none published · Read the receipt →

Minoxidil

Topical minoxidil is an FDA-approved, over-the-counter hair-regrowth drug. It raises VEGF in cultured dermal papilla cells (Lachgar 1998, PMID 9580790); AHK-Cu hasn't been shown to. Some AHK-Cu serums are sold as add-ons to minoxidil; no study has tested the two together.

Finasteride (oral 5-alpha-reductase inhibitor)

Some AHK-Cu serums are sold as add-ons to finasteride; no study has tested the two together.

Biotinyl-GHK / Biotinyl Tripeptide-1 ("Procapil" component)

A biotin-linked form of GHK that sellers list in serums alongside AHK-Cu. No study has tested the combination.

Topical caffeine / adenosine / redensyl / capixyl

Other cosmetic scalp ingredients that sellers list in serums alongside AHK-Cu. No study has tested these combinations.

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Current Status — April 2026

AHK-Cu (Copper Tripeptide-3) is not an FDA-approved drug for any indication. It is classified as a cosmetic ingredient in the U.S. and in most global cosmetic-regulation frameworks (EU Cosmetic Regulation 1223/2009, Japan Quasi-Drug framework for certain applications, Korea KFDA cosmetic classification). As a cosmetic, it is available in leave-on scalp and hair products without prescription.

Cosmetic products containing it typically require compliance with good-manufacturing-practice standards for cosmetics, product-safety dossiers under the EU Cosmetic Regulation, and labeling rules regulating therapeutic-claim language. Claims such as "treats" or "cures" androgenetic alopecia would reclassify the product as a drug and trigger FDA drug-approval requirements; properly marketed AHK-Cu products are positioned as cosmetic ("supports scalp appearance," "improves hair fullness") rather than therapeutic.

AHK-Cu is not named on the WADA Prohibited List. Its topical cosmetic-use profile does not have a clean fit under any S-class or M-class category. A cosmetic-concentration copper tripeptide serum is not a plausible WADA concern.

AHK-Cu is not on the FDA Category 2 Bulk Drug Substances list, and it was not among the 12 peptides FDA removed from that list in April 2026 (FDA 503A categories list, April 22, 2026). As a cosmetic ingredient rather than a compounded drug, AHK-Cu sits in a different regulatory lane entirely — governed by cosmetic-ingredient rules, not compounding-pharmacy rules.

No FDA-approved reference drug product exists for AHK-Cu, and no pharmaceutical sponsor has advanced AHK-Cu through a New Drug Application (NDA) pathway. Given the compound's age, off-patent status, and cosmetic-industry entrenchment, a pharmaceutical development program for AHK-Cu is not anticipated.

Cost & Access

AHK-Cu is broadly available as a cosmetic ingredient. End-consumer finished products (leave-on scalp serums, hair tonics, combination-peptide treatment vials) are sold over-the-counter through cosmetic retailers, specialty hair-loss brands, and direct-to-consumer e-commerce. No prescription is required in the United States, EU, UK, Canada, Australia, or most other jurisdictions for cosmetic-concentration topical formulations.

Cosmetic-grade AHK-Cu powder (research and formulation channel) is sold by specialty peptide suppliers, who list it at >95% HPLC purity, to cosmetic chemists and formulators.

Because AHK-Cu is a cosmetic rather than a compounded drug, FDA’s 2026 changes to its compounding categories did not touch it. Its access pathway has been — and will remain — the cosmetic-ingredient channel rather than the compounding-pharmacy channel. This is a stable regulatory position that is unlikely to change in the near term.

Kalios does not sell AHK-Cu or any other compounds. All information on this page is educational and research-oriented.

Information current as of April 2026. Regulatory positioning, cosmetic-ingredient listings, and market availability are subject to change. Kalios does not sell compounds.

Next Steps

→ GHK-Cu — the glycine-terminus parent →

→ Calculator — vial-to-syringe math →

→ See every Skin & hair compound →

References

Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. doi:10.1007/BF02978833. PMID: 17703734. (The foundational AHK-Cu in-vitro / ex-vivo paper — dermal papilla cell proliferation, ex vivo follicle elongation, anti-apoptotic Bcl-2/Bax and caspase-3/PARP effects, VEGF and TGF-β1 modulation at 10⁻¹² – 10⁻⁹ M.)
Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107(4):409-417. doi:10.1172/JCI11317. PMID: 11181640. (Transgenic VEGF overexpression increases perifollicular vascularization, accelerates hair regrowth, and increases follicle / shaft size; anti-VEGF antibody reduces follicle size — establishes VEGF as a major hair-growth mediator.)
Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138(3):407-411. doi:10.1046/j.1365-2133.1998.02115.x. PMID: 9580790. (Clinically validated positive-control mechanism — DPC VEGF upregulation — that AHK-Cu's mechanism claim parallels.)
Lachgar S, Charveron M, Gall Y, Bonafe JL. Vascular endothelial growth factor is an autocrine growth factor for hair dermal papilla cells. J Invest Dermatol. 1996;106(1):17-23. PMID: 8592070. (Establishes VEGF-DPC autocrine loop — mechanistic substrate for AHK-Cu's DPC proliferation effect.)
Li W, Man XY, Li CM, Chen JQ, Zhou J, Cai SQ, Lu ZF, Zheng M. VEGF induces proliferation of human hair follicle dermal papilla cells through VEGFR-2-mediated activation of ERK. Exp Cell Res. 2012;318(14):1633-1640. doi:10.1016/j.yexcr.2012.05.003. PMID: 22659165. (Downstream VEGFR2-ERK pathway connecting AHK-Cu's VEGF upregulation to DPC proliferation.)
Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. doi:10.1016/0014-5793(88)80509-x. PMID: 3169264. (Foundational copper-peptide class pharmacology at pico-to-nanomolar concentrations — same range AHK-Cu is active in.)
Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520. (Comprehensive review of copper-peptide gene-expression effects — scaffold for AHK-Cu mechanism extrapolation.)
Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26236730. (Multi-pathway copper-peptide mechanism review — foundational context for AHK-Cu positioning.)
Kozlowska U, Blume-Peytavi U, Kodelja V, Sommer C, Goerdt S, Majewski S, Jablonska S, Orfanos CE. Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle. Arch Dermatol Res. 1998;290(12):661-668. doi:10.1007/s004030050370. PMID: 9879835. (Compartment-resolved VEGF expression across DPCs, fibrous sheath, dermal fibroblasts, and follicular keratinocytes — anchors AHK-Cu's dermal-papilla-centered claim.)
Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. doi:10.1163/156856208784909435. PMID: 18644225. (Authoritative Pickart review of the copper-peptide tissue-remodeling framework.)
Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29. doi:10.3390/cosmetics5020029. (Broad copper-peptide review placing AHK-Cu within the wider class context.)
Siméon A, Wegrowski Y, Bontemps Y, Maquart FX. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000;115(6):962-968. doi:10.1046/j.1523-1747.2000.00166.x. PMID: 11121126. (Copper-peptide class effect on extracellular-matrix turnover in wound healing — background for AHK-Cu scalp-regenerative rationale.)
Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A Randomized Evaluator Blinded Study of Effect of Microneedling in Androgenetic Alopecia: A Pilot Study. Int J Trichology. 2013;5(1):6-11. doi:10.4103/0974-7753.114700. PMID: 23960389. (Microneedling + minoxidil RCT — the procedural-adjunct framework AHK-Cu stacks extend.)
Miller DM, DeSilva D, Pickart L, Aust SD. Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Adv Exp Med Biol. 1990;264:79-84. doi:10.1007/978-1-4684-5730-8_11. PMID: 2244543. (Copper-peptide anti-oxidant buffering mechanism — relevant to AHK-Cu's copper-safe-delivery claim.)
Matsuzaki T, Yoshizato K. Role of hair papilla cells on induction and regeneration processes of hair follicles. Wound Repair Regen. 1998;6(6):524-530. doi:10.1046/j.1524-475x.1998.60605.x. PMID: 9893172. (Dermal papilla cell biology as the master regulator of follicle induction and regeneration — the cellular target of AHK-Cu's published activity.)
Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832. doi:10.1155/2012/324832. PMID: 22666519. (Copper-peptide aging-biology review — context for the copper-peptide family's broader systems-biology positioning.)
Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics. 2015;2(3):236-247. doi:10.3390/cosmetics2030236. (Copper-peptide anti-oxidant gene-expression framework — contextualizes AHK-Cu's scalp redox-environment claim.)
Simeon A, Monier F, Emonard H, Gillery P, Birembaut P, Hornebeck W, Maquart FX. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 1999;112(6):957-964. doi:10.1046/j.1523-1747.1999.00606.x. PMID: 10383745. (Copper-peptide MMP modulation — extracellular-matrix framework underpinning copper-peptide regenerative claims.)
FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)